Amgen (AMGN) Change in Inventory (2009 - 2026)
Amgen (AMGN) posted quarterly Change in Inventory of -$18.0 million for Q1 2026, up 93.75% year-over-year from -$9.3 million in Q1 2025, and up 84.87% quarter-over-quarter from -$119.0 million in Q4 2025.
Amgen (AMGN) Change in Inventory (2009 - 2026) Analysis & Trends
Amgen's Change in Inventory history runs 18 years deep, the most recent figure standing at -$18.0 million for Q1 2026.
- In Q1 2026, Change in Inventory rose 93.75% year-over-year to -$18.0 million; the TTM figure through Mar 2026 stood at -$616.0 million (up 69.41% YoY), while the FY2025 annual figure was -$886.0 million, up 65.01% from the prior year.
- Change in Inventory for Q1 2026 stood at -$18.0 million, up from -$119.0 million in the prior quarter.
- The five-year high for Change in Inventory was $241.0 million in Q3 2022, with the low at -$806.0 million in Q1 2024.
- The 5-year median for Change in Inventory is -$119.0 million (2025), against an average of -$187.4 million.
- The sharpest annual moves came in 2022 and 2024: Change in Inventory jumped 402.08% in 2022, then sank 2306.67% in 2024.
- Amgen's Change in Inventory stood at $91.0 million in 2022, then sank by 729.67% to -$573.0 million in 2023, then surged by 43.63% to -$323.0 million in 2024, then soared by 63.16% to -$119.0 million in 2025, then surged by 84.87% to -$18.0 million in 2026.
- Business Quant data shows AMGN's Change in Inventory at -$18.0 million in Q1 2026, -$119.0 million in Q4 2025, and -$240.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 571.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 143.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 31.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 145.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.00 Mn |
| Jun 30, 2026 | 31.00 Mn |
| Mar 31, 2026 | -18.00 Mn |
| Mar 31, 2026 | -18.00 Mn |
| Dec 31, 2025 | -119.00 Mn |
| Dec 31, 2025 | -119.00 Mn |
| Sep 30, 2025 | -240.00 Mn |
| Sep 30, 2025 | -240.00 Mn |
| Jun 30, 2025 | -239.00 Mn |
| Jun 30, 2025 | -239.00 Mn |
| Mar 31, 2025 | -288.00 Mn |
| Mar 31, 2025 | -288.00 Mn |
| Dec 31, 2024 | -323.00 Mn |
| Dec 31, 2024 | -323.00 Mn |
| Sep 30, 2024 | -681.00 Mn |
| Sep 30, 2024 | -681.00 Mn |
| Jun 30, 2024 | -722.00 Mn |
| Jun 30, 2024 | -722.00 Mn |
| Mar 31, 2024 | -806.00 Mn |
| Mar 31, 2024 | -806.00 Mn |